The LUX-Lung 7 study, which was an international, open label, randomized phase II trial comparing afatinib to gefitinib in EGFR mutant advanced or metastatic NSCLC patients, noted that PFS was longer with afatinib (11 months) than gefitinib (10.9 months) but not statistically significant among the subgroup of 26 patients (16%) with asymptomatic brain metastasis (60). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.